New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer

Author's Avatar
Apr 16, 2019
Article's Main Image

Molecular Residual Disease Detected Up to Two Years Prior to Clinical Relapse, with Zero False Positives

PR Newswire